capital · May 18, 2026
Orchestra BioMed Receives $20 Million Payment from Medtronic for BACKBEAT Trial
Share the canonical public link.
Orchestra BioMed announced on May 6, 2026, receipt of a $20 million investment from Medtronic under a previously disclosed strategic financing agreement. The payment supports completion of the BACKBEAT Global Pivotal Trial evaluating AVIM Therapy for patients with uncontrolled hypertension and pacemaker indications. This tranche, combined with a separate $15 million from Ligand Pharmaceuticals announced on May 1, 2026, brings total strategic capital received to $35 million. Orchestra BioMed is a biomedical company accelerating technologies through partnerships with global medical device firms.
Spend governor blocked model creation: provider_circuit_open (lane=battlemap, provider=together)